Drug Profile
PRX 167700
Alternative Names: PRO VAP-1 inh; PRX 167700H; PRX167700Latest Information Update: 26 Feb 2021
Price :
$50
*
At a glance
- Originator Cambridge Biotechnology
- Developer Proximagen
- Class Anti-inflammatories; Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory pain
Most Recent Events
- 18 Oct 2018 Proximagen completes a phase-II clinical trial in Inflammatory pain (Adjunctive treatment) in Czech Republic, Poland, United Kingdom, Hungary and Spain (PO) (EudraCT: 2016-001443-39)
- 23 Sep 2016 Phase-II clinical trials in Inflammatory pain (Adjunctive treatment) in Czech Republic, Poland, United Kingdom, Spain (PO) (EudraCT: 2016-001443-39)
- 20 Sep 2016 Phase-II clinical trials in Inflammatory pain (Adjunctive treatment) in Hungary (PO, Tablet) (EudraCT2016-001443-39)